Skip to main content
Fig. 1 | Cancer Cell International

Fig. 1

From: An antisense amido-bridged nucleic acid gapmer oligonucleotide targeting SRRM4 alters REST splicing and exhibits anti-tumor effects in small cell lung cancer and prostate cancer cells

Fig. 1

SRRM4 ASO affects the cell viability and promote REST splicing change. a SRRM4 mRNA expression analysis in SCLC cells transfected with SRRM4 ASO. SCLC cells (H146 and H209) were transfected with various amounts of ASO (AmNA_7174) and negative control oligonucleotide (AmNA_26). Cells (0.5 × 106) were transfected with SRRM4 ASO and collected 24 h after transfection. RT-qPCR was performed using specific primers, and the 2−ΔΔct values of SRRM4 mRNA expression were normalized to endogenous actin in non-treated cells (NT) as 1.0. The assay was performed 3 times to confirm reproducibility. Data are presented as the mean ± SEM of three independent experiments (n = 3). ***P < 0.001. b REST splicing was analyzed by RT-PCR. Cells were collected after 72 h following transfection and total mRNA was prepared. RT-PCR was performed using specific primers for either REST or β-actin. PCR products were analyzed by electrophoresis using polyacrylamide gels followed by staining. One of three independent experiments is shown. c After 72 h of transfection, cell viability was measured by CellTiter-Glo 3D assay. The assay was performed 3 times to confirm reproducibility. Data are presented as the mean ± SEM of three independent cell cultures (n = 3). Statistic differences were analyzed using one-way analysis of variance (ANOVA) followed by the Student’s t-test ***P < 0.001

Back to article page